Antares Pharma. Medical devices. Has not moved in market cap since 2016, when they were posting 10-12m revenues a quarter. Since then, epipen and xyosted approval, idorsia novel drug contract, Pfizer contract, 250% yearly revenue increase (100% last year). #stocks #WallStreet ⬇️